AKEBIA THERAPEUTICS, INC. Operating Expenses
AKEBIA THERAPEUTICS, INC. (AKBA) reported Operating Expenses of $45.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $45.03M, a 17.07% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $45.95M, a 26.94% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $53.64M, a 32.64% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $44.93M, a 25.61% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. operating expenses for fiscal 2025 was $173.24M, a 17.47% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. operating expenses for fiscal 2024 was $147.47M, a 11.55% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. operating expenses for fiscal 2023 was $166.73M, a 42.05% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. operating expenses for fiscal 2022 was $287.69M, a 11.61% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed | Operating Expenses 85 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $45.03M 10-Q · filed 2026-08-05 | $90.98M 10-Q · filed 2026-08-05 | $144.62M derived: sum of 3 quarters · filed 2026-08-05 | $189.55M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2026-03-31 | $45.95M 10-Q · filed 2026-05-07 | $99.59M derived: sum of 2 quarters · filed 2026-05-07 | $144.52M derived: sum of 3 quarters · filed 2026-05-07 | $182.99M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-12-31 | $53.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $98.57M derived: sum of 2 quarters · filed 2026-02-26 | $137.04M derived: sum of 3 quarters · filed 2026-08-05 | $173.24M 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | $44.93M 10-Q · filed 2025-11-10 | $83.40M derived: sum of 2 quarters · filed 2026-08-05 | $119.59M 10-Q · filed 2025-11-10 | $160.03M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-06-30 | $38.46M 10-Q · filed 2026-08-05 | $74.66M 10-Q · filed 2026-08-05 | $115.10M derived: sum of 3 quarters · filed 2026-08-05 | $150.87M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-03-31 | $36.20M 10-Q · filed 2026-05-07 | $76.64M derived: sum of 2 quarters · filed 2026-05-07 | $112.41M derived: sum of 3 quarters · filed 2026-05-07 | $147.73M derived: sum of 4 quarters · filed 2026-05-07 | |||||
| 2024-12-31 | $40.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $76.21M derived: sum of 2 quarters · filed 2026-02-26 | $111.54M derived: sum of 3 quarters · filed 2026-02-26 | $147.47M 10-K · filed 2026-02-26 | |||||
| 2024-09-30 | $35.77M 10-Q · filed 2025-11-10 | $71.10M derived: sum of 2 quarters · filed 2025-11-10 | $107.04M 10-Q · filed 2025-11-10 | $143.19M derived: sum of 4 quarters · filed 2026-02-26 | |||||
| 2024-06-30 | $35.33M 10-Q · filed 2025-08-07 | $71.26M 10-Q · filed 2025-08-07 | $107.42M derived: sum of 3 quarters · filed 2026-02-26 | $144.49M derived: sum of 4 quarters · filed 2026-02-26 | |||||
| 2024-03-31 | $35.94M 10-Q · filed 2025-05-08 | $72.09M derived: sum of 2 quarters · filed 2026-02-26 | $109.17M derived: sum of 3 quarters · filed 2026-02-26 | $157.26M derived: sum of 4 quarters · filed 2026-02-26 | |||||
| 2023-12-31 | $36.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $73.23M derived: sum of 2 quarters · filed 2026-02-26 | $121.32M derived: sum of 3 quarters · filed 2026-02-26 | $166.73M 10-K · filed 2026-02-26 | |||||
| 2023-09-30 | $37.07M 10-Q · filed 2024-11-07 | $85.16M derived: sum of 2 quarters · filed 2024-11-07 | $130.57M 10-Q · filed 2024-11-07 | $194.65M derived: sum of 4 quarters · filed 2024-11-07 | |||||
| 2023-06-30 | $48.09M 10-Q · filed 2024-08-08 | $93.50M 10-Q · filed 2024-08-08 | $157.58M derived: sum of 3 quarters · filed 2024-08-08 | $218.42M derived: sum of 4 quarters · filed 2024-08-08 | |||||
| 2023-03-31 | $45.41M 10-Q · filed 2024-05-09 | $45.58M 10-Q · filed 2023-05-08 | $109.49M derived: sum of 2 quarters · filed 2024-05-09 | $170.33M derived: sum of 3 quarters · filed 2024-05-09 | $244.02M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $64.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $124.92M derived: sum of 2 quarters · filed 2024-03-14 | $198.61M derived: sum of 3 quarters · filed 2024-03-14 | $287.69M 10-K · filed 2024-03-14 | $286.92M 10-K · filed 2023-03-10 | ||||
| 2022-09-30 | $60.84M 10-Q · filed 2023-11-08 | $59.19M 10-Q · filed 2022-11-03 | $134.53M derived: sum of 2 quarters · filed 2023-11-08 | $223.62M 10-Q · filed 2023-11-08 | $222.30M 10-Q · filed 2022-11-03 | $298.76M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $73.69M 10-Q · filed 2023-08-28 | $74.26M 10-Q · filed 2022-08-04 | $162.78M 10-Q · filed 2023-08-28 | $163.10M 10-Q · filed 2022-08-04 | $237.93M derived: sum of 3 quarters · filed 2023-08-28 | $325.63M derived: sum of 4 quarters · filed 2023-08-28 | |||
| 2022-03-31 | $88.85M 10-Q · filed 2023-05-08 | $164.24M derived: sum of 2 quarters · filed 2023-08-28 | $251.94M derived: sum of 3 quarters · filed 2023-08-28 | $331.69M derived: sum of 4 quarters · filed 2023-08-28 | |||||
| 2021-12-31 | $75.39M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $163.09M derived: sum of 2 quarters · filed 2023-08-28 | $242.85M derived: sum of 3 quarters · filed 2023-08-28 | $325.48M 10-K/A · filed 2023-08-28 | $325.50M 10-K · filed 2022-03-01 | ||||
| 2021-09-30 | $87.70M 10-Q · filed 2022-11-03 | $167.46M derived: sum of 2 quarters · filed 2022-11-03 | $250.09M 10-Q · filed 2022-11-03 | $328.96M derived: sum of 4 quarters · filed 2022-11-03 | |||||
| 2021-06-30 | $79.76M 10-Q · filed 2022-08-04 | $162.39M 10-Q · filed 2022-08-04 | $241.26M derived: sum of 3 quarters · filed 2022-08-04 | $329.00M derived: sum of 4 quarters · filed 2022-08-04 | |||||
| 2021-03-31 | $82.63M 10-Q · filed 2022-05-09 | $161.50M derived: sum of 2 quarters · filed 2022-05-09 | $249.24M derived: sum of 3 quarters · filed 2022-05-09 | $338.58M derived: sum of 4 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | $78.87M 10-K · filed 2021-02-25 | $166.61M derived: sum of 2 quarters · filed 2021-11-04 | $255.95M derived: sum of 3 quarters · filed 2021-11-04 | $375.99M 10-K/A · filed 2023-08-28 | $375.84M 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | $87.74M 10-Q · filed 2021-11-04 | $177.08M derived: sum of 2 quarters · filed 2021-11-04 | $296.97M 10-Q · filed 2021-11-04 | $423.27M derived: sum of 4 quarters · filed 2021-11-04 | |||||
| 2020-06-30 | $89.34M 10-Q · filed 2021-08-05 | $209.24M 10-Q · filed 2021-08-05 | $335.53M derived: sum of 3 quarters · filed 2021-08-05 | $445.15M derived: sum of 4 quarters · filed 2021-08-05 | |||||
| 2020-03-31 | $119.89M 10-Q · filed 2021-05-10 | $246.19M derived: sum of 2 quarters · filed 2021-05-10 | $355.81M derived: sum of 3 quarters · filed 2021-05-10 | $478.46M derived: sum of 4 quarters · filed 2021-05-10 | |||||
| 2019-12-31 | $126.30M 10-K · filed 2021-02-25 | $235.92M derived: sum of 2 quarters · filed 2021-02-25 | $358.57M derived: sum of 3 quarters · filed 2021-02-25 | $475.95M 10-K · filed 2022-03-01 | |||||
| 2019-09-30 | $109.62M 10-K · filed 2021-02-25 | $232.28M derived: sum of 2 quarters · filed 2021-02-25 | $349.65M 10-Q · filed 2020-11-05 | $491.89M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2019-06-30 | $122.66M 10-K · filed 2021-02-25 | $240.03M 10-Q · filed 2020-08-10 | $382.27M derived: sum of 3 quarters · filed 2021-02-25 | $463.29M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2019-03-31 | $117.38M 10-K · filed 2021-02-25 | $259.62M derived: sum of 2 quarters · filed 2021-02-25 | $340.63M derived: sum of 3 quarters · filed 2021-02-25 | $425.08M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2018-12-31 | $142.24M 10-K · filed 2020-03-12 | $223.25M derived: sum of 2 quarters · filed 2020-03-12 | $307.71M derived: sum of 3 quarters · filed 2020-03-12 | $378.13M 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | $81.01M 10-K · filed 2020-03-12 | $165.47M derived: sum of 2 quarters · filed 2020-03-12 | $235.90M 10-Q · filed 2019-11-12 | $311.84M derived: sum of 4 quarters · filed 2020-03-12 | |||||
| 2018-06-30 | $84.45M 10-K · filed 2020-03-12 | $154.88M 10-Q · filed 2019-08-08 | $230.83M derived: sum of 3 quarters · filed 2020-03-12 | $296.29M derived: sum of 4 quarters · filed 2020-03-12 | |||||
| 2018-03-31 | $70.43M 10-K · filed 2020-03-12 | $146.38M derived: sum of 2 quarters · filed 2020-03-12 | $211.84M derived: sum of 3 quarters · filed 2020-03-12 | $262.49M derived: sum of 4 quarters · filed 2020-03-12 | |||||
| 2017-12-31 | $75.95M 10-K · filed 2019-03-26 | $141.41M derived: sum of 2 quarters · filed 2019-03-26 | $192.06M derived: sum of 3 quarters · filed 2019-03-26 | $257.90M 10-K · filed 2020-03-12 | |||||
| 2017-09-30 | $65.46M 10-K · filed 2019-03-26 | $116.11M derived: sum of 2 quarters · filed 2019-03-26 | $181.95M 10-Q · filed 2018-11-08 | $221.53M derived: sum of 4 quarters · filed 2019-03-26 | |||||
| 2017-06-30 | $50.66M 10-K · filed 2019-03-26 | $116.49M 10-Q · filed 2018-08-08 | $156.07M derived: sum of 3 quarters · filed 2019-03-26 | $192.25M derived: sum of 4 quarters · filed 2019-03-26 | |||||
| 2017-03-31 | $65.84M 10-K · filed 2019-03-26 | $105.42M derived: sum of 2 quarters · filed 2019-03-26 | $141.60M derived: sum of 3 quarters · filed 2019-03-26 | $177.79M derived: sum of 4 quarters · filed 2019-03-26 | |||||
| 2016-12-31 | $39.58M 10-K · filed 2018-03-12 | $75.76M derived: sum of 2 quarters · filed 2018-03-12 | $111.95M derived: sum of 3 quarters · filed 2018-03-12 | $138.00M 10-K · filed 2019-03-26 | |||||
| 2016-09-30 | $36.18M 10-K · filed 2018-03-12 | $72.37M derived: sum of 2 quarters · filed 2018-03-12 | $98.42M 10-Q · filed 2017-11-08 | $118.47M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-06-30 | $36.19M 10-K · filed 2018-03-12 | $62.23M 10-Q · filed 2017-08-08 | $82.28M derived: sum of 3 quarters · filed 2018-03-12 | $101.96M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-03-31 | $26.05M 10-K · filed 2018-03-12 | $46.10M derived: sum of 2 quarters · filed 2018-03-12 | $65.77M derived: sum of 3 quarters · filed 2018-03-12 | $76.66M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2015-12-31 | $20.05M 10-K · filed 2017-03-06 | $39.73M derived: sum of 2 quarters · filed 2017-03-06 | $50.62M derived: sum of 3 quarters · filed 2017-03-06 | $61.51M 10-K · filed 2018-03-12 | |||||
| 2015-09-30 | $19.68M 10-K · filed 2017-03-06 | $30.57M derived: sum of 2 quarters · filed 2017-03-06 | $41.46M 10-Q · filed 2016-11-09 | $52.07M derived: sum of 4 quarters · filed 2017-03-06 | |||||
| 2015-06-30 | $10.89M 10-K · filed 2017-03-06 | $21.79M 10-Q · filed 2016-08-08 | $32.39M derived: sum of 3 quarters · filed 2017-03-06 | $41.98M derived: sum of 4 quarters · filed 2017-03-06 | |||||
| 2015-03-31 | $10.90M 10-K · filed 2017-03-06 | $21.50M derived: sum of 2 quarters · filed 2017-03-06 | $31.09M derived: sum of 3 quarters · filed 2017-03-06 | $38.93M derived: sum of 4 quarters · filed 2017-03-06 | |||||
| 2014-12-31 | $10.61M 10-K · filed 2016-03-14 | $20.19M derived: sum of 2 quarters · filed 2016-03-14 | $28.03M derived: sum of 3 quarters · filed 2016-03-14 | $37.94M 10-K · filed 2017-03-06 | |||||
| 2014-09-30 | $9.58M 10-K · filed 2016-03-14 | $17.42M derived: sum of 2 quarters · filed 2016-03-14 | $27.33M 10-Q · filed 2015-11-09 | $33.53M derived: sum of 4 quarters · filed 2016-03-14 | |||||
| 2014-06-30 | $7.84M 10-K · filed 2016-03-14 | $7.84M 10-Q · filed 2014-08-11 | $17.75M 10-Q · filed 2015-08-11 | $17.75M 10-Q · filed 2014-08-11 | $23.95M derived: sum of 3 quarters · filed 2016-03-14 | $27.98M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2014-03-31 | $9.91M 10-K · filed 2016-03-14 | $9.91M 10-Q · filed 2014-05-12 | $16.11M derived: sum of 2 quarters · filed 2016-03-14 | $20.14M derived: sum of 3 quarters · filed 2016-03-14 | $23.27M derived: sum of 4 quarters · filed 2016-03-14 | $76.93M 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $6.20M 10-K · filed 2015-03-04 | $10.23M derived: sum of 2 quarters · filed 2015-03-04 | $13.36M derived: sum of 3 quarters · filed 2015-03-04 | $15.93M 10-K · filed 2016-03-14 | |||||
| 2013-09-30 | $4.03M 10-K · filed 2015-03-04 | $7.16M derived: sum of 2 quarters · filed 2015-03-04 | $9.73M 10-Q · filed 2014-11-10 | ||||||
| 2013-06-30 | $3.12M 10-K · filed 2015-03-04 | $3.12M 10-Q · filed 2014-08-11 | $5.70M 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | $2.58M 10-K · filed 2015-03-04 | $2.58M 10-Q · filed 2014-05-12 | |||||||
| 2012-12-31 | $8.52M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |